CD8A and neoplasm: In some studies, tumor mutational load [29, 30] , chromosomal instability [31], intensity of CD8+ T cell infiltrates [32, 33] and intratumoral PD-L1 expression [34, 35] have been reported as biomarkers for responsiveness to immune checkpoint inhibitors.